Unverified50% confidenceFactExact time
Currently the primary endpoints of most large GLP-1 trials (such as SELECT and the STEP series) are cardiovascular events or weight change, not aging indicators.
1
Sources
50%
Confidence
Medium-term (~90 days)
Relevance
10/17/2026
First Seen
Valid until: 1/15/2027
Sources
Related Entities
Related Claims
UnverifiedConfirming the effect of GLP-1 on biological aging requires rigorously designed long-term clinical trials with aging-related biomarkers as primary endpoints and with confounding factors from lifestyle changes distinguished from drug effects.72% similarUnverifiedThe evidence linking GLP-1 and biological age comes from conference reports, is still at an early stage, and requires peer review and larger-scale validation.68% similarUnverifiedAt present, GLP-1 drugs slowing biological aging remains a research direction in an early exploratory stage rather than a confirmed clinical conclusion.68% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/1054433API
curl https://kongchang.com/api/v1/knowledge/claims/1054433MCP
get_claim(id=1054433)